Skip to main content

Volume 1 Supplement 1

Abstracts of the 28th Annual Scientific Meeting of the Society for Immunotherapy of Cancer (SITC)

HLA-G-specific microRNAs a novel approach for targeting tumors

Immune inhibitory molecules on immune cells as well as on tumor cells appear to play a key role in modulating the immunogenicity of tumors and the efficacy of immunotherapies. One mediator is represented by the non-classical HLA-G antigen, which is often overexpressed in human tumors when compared to corresponding normal tissues thereby inhibiting both innate as well as adaptive immune responses. Since discordant HLA-G transcript and protein expression levels were often found in tumors of distinct origin posttranscriptional control mechanisms have been recently suggested. Indeed, different HLA-G-specific miRs have been identified, which were able to downregulate HLA-G surface expression. The miR-mediated inhibition of HLA-G enhanced the NK cell recognition. These miRs were also differentially expressed in renal cell carcinoma (RCC) versus normal kidney epithelium. Immunohistochemical analysis demonstrated of a high frequency HLA-G expression in RCC lesions, which was associated with disease progression and inversely correlated with the expression of HLA-G-specific miRs. These data postulate that HLA-G-specific miRs might be used as prognostic markers as well as potential therapeutics for targeting HLA-G expressing RCC.

Author information



Corresponding author

Correspondence to Barbara Seliger.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Jasinski-Bergner, S., Hartmann, A., Spath, V. et al. HLA-G-specific microRNAs a novel approach for targeting tumors. j. immunotherapy cancer 1, P174 (2013).

Download citation


  • Renal Cell Carcinoma
  • Prognostic Marker
  • Surface Expression
  • Adaptive Immune Response
  • Protein Expression Level